Vanguard Group
FRTX

Vanguard Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Vanguard Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,060
Closed -$22.4K – 4533
2023
Q3 		$22.4K Hold
23,060
– – ﹤0.01% 4488
2023
Q2 		$16.2K Hold
23,060
– – ﹤0.01% 4527
2023
Q1 		$15.2K Sell
23,060
-4,719
-17% -$7.88K ﹤0.01% 4537
2022
Q4 		$41.7K Hold
27,779
– – ﹤0.01% 4458
2022
Q3 		$50K Sell
27,779
-41,199
-60% -$119K ﹤0.01% 4545
2022
Q2 		$391K Sell
68,978
-180
-0.3% -$1.63K ﹤0.01% 4348
2022
Q1 		$832K Buy
69,158
+8,918
+15% +$96.5K ﹤0.01% 4266
2021
Q4 		$621K Sell
60,240
-505
-0.8% -$9.07K ﹤0.01% 4386
2021
Q3 		$1.97M Buy
60,745
+2,937
+5% +$95.3K ﹤0.01% 4060
2021
Q2 		$2.48M Buy
57,808
+19,182
+50% +$789K ﹤0.01% 3908
2021
Q1 		$1.9M Buy
38,626
+9,969
+35% +$547K ﹤0.01% 3873
2020
Q4 		$1.01M Buy
28,657
+14,566
+103% +$458K ﹤0.01% 3824
2020
Q3 		$573K Buy
14,091
+6,249
+80% +$246K ﹤0.01% 3785
2020
Q2 		$353K Buy
7,842
+5,155
+192% +$275K ﹤0.01% 3842
2020
Q1 		$144K Buy
2,687
+1,461
+119% +$114K ﹤0.01% 3903
2019
Q4 		$83K Hold
1,226
– – ﹤0.01% 4024
2019
Q3 		$229K Sell
1,226
-604
-33% -$139K ﹤0.01% 3946
2019
Q2 		$490K Hold
1,830
– – ﹤0.01% 3830
2019
Q1 		$692K Sell
1,830
-8
-0.4% -$2.68K ﹤0.01% 3715
2018
Q4 		$683K Sell
1,838
-323
-15% -$127K ﹤0.01% 3666
2018
Q3 		$933K Buy
2,161
+17
+0.8% +$7.17K ﹤0.01% 3736
2018
Q2 		$776K Buy
2,144
+408
+24% +$192K ﹤0.01% 3749
2018
Q1 		$793K Buy
1,736
+310
+22% +$154K ﹤0.01% 3703
2017
Q4 		$822K Buy
1,426
+894
+168% +$589K ﹤0.01% 3654
2017
Q3 		$402K Buy
532
+215
+68% +$170K ﹤0.01% 3791
2017
Q2 		$271K Sell
317
-381
-55% -$279K ﹤0.01% 3848
2017
Q1 		$490K Buy
698
+47
+7% +$33.1K ﹤0.01% 3757
2016
Q4 		$471K Sell
651
-90
-12% -$73.1K ﹤0.01% 3743
2016
Q3 		$710K Sell
741
-25
-3% -$31.5K ﹤0.01% 3667
2016
Q2 		$1.09M Buy
766
+15
+2% +$19.3K ﹤0.01% 3585
2016
Q1 		$925K Buy
751
+6
+0.8% +$6.92K ﹤0.01% 3621
2015
Q4 		$962K Sell
745
-18
-2% -$23.5K ﹤0.01% 3641
2015
Q3 		$1.11M Buy
763
+26
+4% +$50.2K ﹤0.01% 3603
2015
Q2 		$1.63M Buy
737
+14
+2% +$43.9K ﹤0.01% 3500
2015
Q1 		$2.15M Buy
723
+41
+6% +$131K ﹤0.01% 3379
2014
Q4 		$2.26M Buy
682
+23
+3% +$81.5K ﹤0.01% 3240
2014
Q3 		$2.32M Buy
659
+51
+8% +$198K ﹤0.01% 3201
2014
Q2 		$2.34M Sell
608
-31
-5% -$117K ﹤0.01% 3198
2014
Q1 		$2.6M Buy
639
+104
+19% +$464K ﹤0.01% 3109
2013
Q4 		$1.99M Sell
535
-181
-25% -$686K ﹤0.01% 3186
2013
Q3 		$2.82M Buy
716
+17
+2% +$128K ﹤0.01% 3004
2013
Q2 		$6.9M Buy
+699
New +$7.74M ﹤0.01% 2499

Other funds holding FRTX

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Vanguard Group's FRTX Position: Q4 2023 in Review

Vanguard Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2023, closing a stake of 23,060 shares — an estimated $22.4K sold.

Vanguard Group first reported a position in FRTX in Q2 2013 and held it in 42 quarters. The position peaked at $6.9M in Q2 2013. 1 fund tracked by Wall St. Rank holds FRTX as of Q4 2023.

  • Vanguard Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 23,060 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $22.4K.
  • Vanguard Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 42 quarters.
  • Vanguard Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $6.9M in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.